Emerging treatments

TNF-alpha antagonists

In one case report, etanercept was shown to improve synovitis in a patient with FS, but it also decreased neutrophil count.[27] In another case report, etanercept had no effect on neutrophil count after 2 weeks of treatment and caused a severe cutaneous allergic reaction.[22] The role of TNF-alpha antagonists in FS is limited, primarily because of concerns over increased risk of infection.

Other biological agents

Case studies report treatment of FS with abatacept and with tocilizumab.[28][29]

Use of this content is subject to our disclaimer